Adamantidis M M
Laboratoire de pharmacologie, Faculté de médecine, Lille.
Arch Mal Coeur Vaiss. 1995 Jan;88 Spec No 1:33-40.
Vaughan-Williams class III antiarrhythmic agents act mainly by prolonging the duration of the cardiac action potential and, thus, the refractory period. This effect may be obtained: 1) by increasing the inward sodium or calcium currents, which may lead to an intracellular calcium overload and induce a very proarrhythmic situation, or 2) by decreasing the outward potassium currents, the objective of the new class III antiarrhythmic drugs under development. They selectively block one or several potassium channels regulated by the membrane potential (transient outward current Ito, delayed rectifying current IK and rectifying inward current IK1). Under physiological conditions the blockade of potassium channels regulated by a ligand (for example, ATP-dependent) does not lead to a class III effect. Prolongation of ventricular repolarisation is accompanied by a slowing of the heart rate and a positive inotropic effect. It is attenuated by rapid rhythms and amplified by slow rhythms: this is the reverse frequency-dependent phenomenon. However, normal frequency dependence (or "use-dependence") has been reported with the ionic channel, this paradox apparently being related to the complexity of the relations between the relative contributions of the ionic currents of repolarisation and their modulation by the heart rate. The class III effect confers a proarrhythmic potential and may lead to torsades de pointes, favorised by bradycardia, hypokalaemia and hypomagnesaemia. Experimentally, it favorises early after depolarisations which are presumed to be the cellular trigger event. The comprehension of factors influencing the antiarrhythmic and proarrhythmic class III effects has led to the establishment of a pharmacological profile of the "ideal" drug conferring the least proarrhythmic risk and the best efficacy.
Vaughan-Williams III类抗心律失常药物主要通过延长心脏动作电位的持续时间,从而延长不应期来发挥作用。这种效应可通过以下方式获得:1)增加内向钠电流或钙电流,这可能导致细胞内钙超载并引发非常严重的促心律失常情况,或者2)减少外向钾电流,这是正在研发的新型III类抗心律失常药物的目标。它们选择性地阻断一个或几个受膜电位调节的钾通道(瞬时外向电流Ito、延迟整流电流IK和内向整流电流IK1)。在生理条件下,由配体(例如,ATP依赖性)调节的钾通道的阻断不会导致III类效应。心室复极的延长伴随着心率减慢和正性肌力作用。快速心律可使其减弱,缓慢心律可使其增强:这就是反向频率依赖性现象。然而,离子通道也存在正常的频率依赖性(或“使用依赖性”),这种矛盾现象显然与复极化离子电流的相对贡献及其受心率调节之间关系的复杂性有关。III类效应具有促心律失常的潜在风险,可能导致尖端扭转型室速,心动过缓、低钾血症和低镁血症会加重这种情况。在实验中,它有利于早期后除极,而早期后除极被认为是细胞触发事件。对影响III类抗心律失常和促心律失常效应的因素的理解,促使人们建立了一种“理想”药物的药理学特征,这种药物具有最低的促心律失常风险和最佳的疗效。